See more : Bever Holding NV (BEVER.AS) Income Statement Analysis – Financial Results
Complete financial analysis of SI-BONE, Inc. (SIBN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SI-BONE, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Open Text Corporation (OTEX.TO) Income Statement Analysis – Financial Results
- Aemulus Holdings Berhad (0181.KL) Income Statement Analysis – Financial Results
- Home Reit Plc (HMRPF) Income Statement Analysis – Financial Results
- Strandline Resources Limited (STA.AX) Income Statement Analysis – Financial Results
- AINAVO HOLDINGS Co.,Ltd. (7539.T) Income Statement Analysis – Financial Results
SI-BONE, Inc. (SIBN)
About SI-BONE, Inc.
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 138.89M | 106.41M | 90.15M | 73.39M | 67.30M | 55.38M | 47.98M | 42.10M | 41.17M | 40.05M | 49.00M | 37.02M |
| Cost of Revenue | 29.47M | 15.71M | 10.43M | 8.90M | 6.79M | 4.83M | 5.11M | 5.17M | 5.40M | 6.50M | 4.33M | 3.04M |
| Gross Profit | 109.42M | 90.70M | 79.72M | 64.49M | 60.51M | 50.55M | 42.87M | 36.94M | 35.78M | 33.55M | 44.67M | 33.98M |
| Gross Profit Ratio | 78.78% | 85.24% | 88.43% | 87.87% | 89.91% | 91.27% | 89.35% | 87.73% | 86.89% | 83.77% | 91.16% | 91.78% |
| Research & Development | 15.03M | 13.63M | 12.44M | 9.46M | 7.28M | 5.38M | 5.51M | 6.38M | 8.61M | 9.17M | 8.37M | 3.77M |
| General & Administrative | 31.07M | 28.96M | 25.07M | 19.80M | 20.98M | 12.64M | 13.06M | 12.91M | 13.79M | 10.06M | 6.85M | 5.23M |
| Selling & Marketing | 110.25M | 107.73M | 93.88M | 73.79M | 68.25M | 44.50M | 41.65M | 35.22M | 39.80M | 40.63M | 34.74M | 35.69M |
| SG&A | 141.32M | 136.69M | 118.95M | 93.59M | 89.24M | 57.14M | 54.71M | 48.12M | 53.59M | 50.68M | 41.59M | 40.92M |
| Other Expenses | 0.00 | -132.00K | 277.00K | -126.00K | -2.00K | -1.15M | 340.00K | 213.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 156.35M | 150.31M | 131.39M | 103.05M | 96.51M | 62.51M | 60.22M | 54.50M | 62.20M | 59.84M | 49.90M | 44.65M |
| Cost & Expenses | 185.82M | 166.02M | 141.82M | 111.95M | 103.30M | 67.35M | 65.33M | 59.67M | 67.60M | 66.34M | 54.23M | 47.69M |
| Interest Income | 6.92M | 1.30M | 186.00K | 1.10M | 2.55M | 769.00K | 175.00K | 71.00K | 1.66M | 1.52M | 909.00K | 226.00K |
| Interest Expense | 3.46M | 2.82M | 5.37M | 6.10M | 4.95M | 5.49M | 6.20M | 3.31M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.43M | 3.45M | 2.09M | 1.13M | 774.00K | 722.00K | 1.01M | 1.04M | 786.00K | 287.00K | 50.00K | 42.00K |
| EBITDA | -34.45M | -54.99M | -49.58M | -36.47M | -32.68M | -11.62M | -15.82M | -16.24M | -25.68M | -26.01M | -5.25M | -10.68M |
| EBITDA Ratio | -24.80% | -54.92% | -56.80% | -51.23% | -49.71% | -21.61% | -32.97% | -38.58% | -62.27% | -64.95% | -10.71% | -28.84% |
| Operating Income | -46.93M | -59.61M | -51.67M | -38.57M | -36.00M | -11.97M | -17.35M | -17.57M | -26.42M | -26.30M | -5.30M | -10.72M |
| Operating Income Ratio | -33.79% | -56.02% | -57.31% | -52.55% | -53.50% | -21.61% | -36.16% | -41.72% | -64.18% | -65.66% | -10.81% | -28.96% |
| Total Other Income/Expenses | 3.60M | -1.65M | -4.90M | -5.13M | -2.40M | -5.49M | -5.69M | -3.02M | -1.73M | -1.50M | -847.00K | -184.00K |
| Income Before Tax | -43.34M | -61.26M | -56.57M | -43.70M | -38.40M | -17.45M | -23.04M | -20.59M | -28.15M | -27.80M | -6.14M | -10.90M |
| Income Before Tax Ratio | -31.20% | -57.57% | -62.75% | -59.54% | -57.06% | -31.51% | -48.01% | -48.90% | -68.38% | -69.42% | -12.54% | -29.45% |
| Income Tax Expense | 0.00 | 1.65M | 3.56M | 4.85M | 4.17M | 5.49M | 5.69M | 3.02M | 0.00 | 2.00K | 10.00K | 0.00 |
| Net Income | -43.34M | -62.90M | -60.13M | -48.54M | -42.58M | -17.45M | -23.04M | -20.59M | -28.15M | -27.81M | -6.15M | -10.90M |
| Net Income Ratio | -31.20% | -59.11% | -66.70% | -66.15% | -63.26% | -31.51% | -48.01% | -48.90% | -68.38% | -69.42% | -12.56% | -29.45% |
| EPS | -1.13 | -1.84 | -1.81 | -1.67 | -1.72 | -1.10 | -1.66 | -1.33 | -1.17 | -10.42 | -2.69 | -5.76 |
| EPS Diluted | -1.13 | -1.84 | -1.81 | -1.67 | -1.72 | -1.10 | -1.66 | -1.33 | -1.17 | -10.42 | -2.69 | -5.76 |
| Weighted Avg Shares Out | 38.43M | 34.20M | 33.15M | 29.06M | 24.71M | 15.90M | 13.87M | 15.48M | 24.08M | 2.67M | 2.29M | 1.89M |
| Weighted Avg Shares Out (Dil) | 38.43M | 34.20M | 33.15M | 29.06M | 24.71M | 15.90M | 13.87M | 15.48M | 24.08M | 2.67M | 2.29M | 1.89M |
SI-BONE, Inc. (SIBN) CEO Laura Francis on Q2 2022 Results - Earnings Call Transcript
SI-BONE, Inc. (NASDAQ:SIBN ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Matt Bacso - IR, Gilmartin Group Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants David Saxon...
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
Si-Bone (SIBN) delivered earnings and revenue surprises of -10.20% and 1.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Si-Bone (SIBN) to Report a Decline in Earnings: What to Look Out for
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SI-BONE, Inc.'s (SIBN) CEO Laura Francis on Q1 2022 Results - Earnings Call Transcript
SI-BONE, Inc. (NASDAQ:SIBN ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Matt Basco - IR, Gilmartin Group Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou...
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
Si-Bone (SIBN) delivered earnings and revenue surprises of -20.93% and 0.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Si-Bone (SIBN) Q1 Earnings Expected to Decline
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SI-BONE To Present at BofA Securities 2022 Healthcare Conference
SANTA CLARA, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2022 Bank of...
SI-BONE, Inc. (SIBN) CEO Laura Francis On Q4 2021 Results - Earnings Call Transcript
SI-BONE, Inc. (SIBN) CEO Laura Francis On Q4 2021 Results - Earnings Call Transcript
SI-BONE's (SIBN) CEO Laura Francis on Q3 2021 Results - Earnings Call Transcript
SI-BONE's (SIBN) CEO Laura Francis on Q3 2021 Results - Earnings Call Transcript
Si-Bone (SIBN) Reports Q3 Loss, Lags Revenue Estimates
Si-Bone (SIBN) delivered earnings and revenue surprises of -17.07% and -1.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Source: https://incomestatements.info
Category: Stock Reports